18F-LN1 PET/CT in Urothelial Carcinomas
NCT06120413 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2023-11-07
Summary
The clinical feasibility of 18F-LN1 PET/CT will be evaluated in 30 patients with urothelial carcinoma, and the results will be compared with those of 18F-FDG.
Conditions
Sponsors & Collaborators
-
Sichuan Provincial People's Hospital
lead OTHER
Principal Investigators
-
Hao Wang · Sichuan Provincial People's Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-11-01
- Primary Completion
- 2024-09-30
- Completion
- 2024-10-31
Countries
- China
Study Locations
More Related Trials
-
68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
NCT05637034 ·Status: UNKNOWN ·Phase: NA
-
68Ga-N188 PET/CT Imaging in Malignancy
NCT05593107 ·Status: RECRUITING ·Phase: NA
-
Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma
NCT05681234 ·Status: COMPLETED ·Phase: NA
-
18F-AlF-FAPi-04 PET/CT Imaging in Patients With Solid Tumor
NCT06126705 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
68Ga-BNU-PSMA PET/CT in Patients With Various Types of Cancer
NCT04525612 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
18F-FAPI PET/CT in Patients With Various Types of Cancer
NCT05810324 ·Status: UNKNOWN ·Phase: NA
-
Evaluating the Usefulness of 18F-AlF-FAPI PET/ CT in Orbital Neoplasms
NCT06791226 ·Status: RECRUITING ·Phase: NA
-
18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma
NCT04588064 ·Status: COMPLETED ·Phase: NA
-
Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
NCT06690216 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression
NCT05749289 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors
NCT06148220 ·Status: RECRUITING ·Phase: NA
-
CLDN18.2 Targeting PET Imaging in Patients With Gastrointestinal Tumors
NCT04883970 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Exploring the Clinical Application Value of CAIX-Targeted PET Imaging in Renal Cancer Patients
NCT06956144 ·Status: RECRUITING
-
PD-L1 Targeting Molecular Imaging of Solid Tumors
NCT04629326 ·Status: RECRUITING ·Phase: NA
-
Clinical Study of CLDN18.2 PET/CT for Noninvasive Diagnosis of Gastric and Pancreatic Cancer
NCT06203613 ·Status: RECRUITING ·Phase: NA
-
Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors
NCT07301814 ·Status: RECRUITING
-
18F-FAPI-04 PET/CT and PET/MR in Patients With Various Types of Malignant Tumors
NCT06557590 ·Status: RECRUITING
-
Clinic Study of 18F-Al-NOTA-MATBBN in Cancer Diagnostics
NCT03094897 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
[68Ga]Ga-NOTA-RW102 PET Imaging in the Diagnosis of PD-L1-expressing Lung Cancer
NCT06165874 ·Status: RECRUITING ·Phase: NA
-
CD70-targeted immunoPET Imaging of Kidney Cancer
NCT06680089 ·Status: RECRUITING ·Phase: PHASE2
-
Positron Emission Tomography (PET) Study for Staging of Muscle Invasive Bladder Cancer
NCT01655745 ·Status: COMPLETED ·Phase: NA
-
Retrospective Review of FDG PET MRI Management of Patients With Muscle Invasive Bladder Cancer
NCT03327883 ·Status: COMPLETED
-
18F-FAPI-RGD PET/CT in Various Tumor Types
NCT06094530 ·Status: RECRUITING
-
Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms
NCT03288597 ·Status: UNKNOWN
-
18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma
NCT04813705 ·Status: RECRUITING ·Phase: PHASE2